2016
DOI: 10.4081/reumatismo.2016.889
|View full text |Cite
|
Sign up to set email alerts
|

Critical finger ischemia and myocardial fibrosis development after sudden interruption of sildenafil treatment in a systemic sclerosis patient

Abstract: summary Systemic sclerosis (SSc) is a connective tissue disease frequently associated with Raynaud's Phenomenon (RP). Among possible pharmacological treatments, phosphodiesterase 5 inhibitors are considered in cases of severe non -responsive RP. We present the case of a male SSc patient wh presented with critical finger ischemia and concomitant appearance of myocardial fibrosis after sudden interruption of sildenafil treatment.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2017
2017
2021
2021

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 10 publications
(5 reference statements)
0
1
0
Order By: Relevance
“…Currently proposed diagnostic sets of assessments, 28 frequency of the recommended testing and minimum dataset 26 and experience-based suggestion for use of wider tools (such as cardiac MRI and stress tests) 26,27 can be reviewed in the light of this new proposed SSc-pHI definition. Our future research agenda includes studies to better capture prevalence and prognostic impact including early SSc stages when SSc-pHI may be asymptomatic and subclinical, 40 as well as optimizing and tailoring use of cardiac assessments in the early diagnosis and follow-up of SSc-pHI. 41…”
Section: Discussionmentioning
confidence: 99%
“…Currently proposed diagnostic sets of assessments, 28 frequency of the recommended testing and minimum dataset 26 and experience-based suggestion for use of wider tools (such as cardiac MRI and stress tests) 26,27 can be reviewed in the light of this new proposed SSc-pHI definition. Our future research agenda includes studies to better capture prevalence and prognostic impact including early SSc stages when SSc-pHI may be asymptomatic and subclinical, 40 as well as optimizing and tailoring use of cardiac assessments in the early diagnosis and follow-up of SSc-pHI. 41…”
Section: Discussionmentioning
confidence: 99%